Pfizer & Lilly's Pain Candidate Succeeds In Back Pain Study
Zacks Investment Research | Feb 19, 2019 08:42PM ET
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced that a higher dose of their NGF inhibitor, tanezumab, met the primary endpoint in a phase III study, evaluating it in patients with chronic low back pain (“CLBP”).
In the past six months, shares of Pfizer have risen 1% compared with the industry ’s gain of 1.6%.
The phase III study evaluated two dosages – 5 mg or 10 mg – of tanezumab, a non-opioid candidate, subcutaneously administered every eight weeks for 56 weeks in patients with moderate-to-severe CLBP, followed by 24-week safety follow-up period. The eligible patients experienced inadequate relief or are intolerant to analgesics and suffering from the disease for more than three consecutive months.
Top-line data from the study showed that treatment with the 10 mg dose of tanezumab led to a statistically significant improvement in pain compared to placebo after 16 weeks of treatment. Although the lower dose of 5mg demonstrated numerical improvement in pain compared to placebo, it did not achieve statistical significance. Detailed results from the study will be submitted for future scientific publication and presentation.
The company estimates that there are 8 million patients with moderate-to-severe CLBP in the United States, which represents a significant opportunity for the candidate as currently available therapies do not have adequate patient response.
Apart from CLBP, tanezumab is also being developed for other pain indications, osteoarthritis and cancer pain. The companies have successfully completed two late-stage studies evaluating tanezumab in patients with osteoarthritis pain.
Tanezumab works by inhibiting nerve growth factor, which suppresses pain signal in the body. Its approval will provide a safer pain medication for patients in the United States where opioid abuse is widespread and patients are largely underserved by the existing medications.
We remind investors that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Limited (NYSE:TEVA) are also developing a NGF antibody, fasinumab for treating osteoarthritis pain.
In a separate press release, Pfizer announced that the European Commission has granted approval to Zirabev (bevacizumab), its biosimilar version of Roche’s cancer drug, Avastin. Zirabev is approved for the treatment of several cancer indications, for which the reference product is approved like colon cancer, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (“NSCLC”), among others.
This is Pfizer’s second oncology biosimilar to be approved in Europe, the first being Roche’s another cancer drug, Herceptin. Meanwhile, Zirabev is also under review in the United States along with biosimilar versions of Rituxan and Herceptin with FDA decisions on all expected in 2019.
Get The News You Want
Pfizer Inc. Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.